SOURCE: IsoRay Medical, Inc.

IsoRay Medical, Inc.

December 16, 2015 08:30 ET

Weill Cornell Medical Clinical Study Demonstrates Cesium-131 Brachytherapy Seeds on a String Surgical Technique Promotes Dose Homogeneity and Minimizes the Risk of Radiation-Induced Injury

RICHLAND, WA--(Marketwired - December 16, 2015) - IsoRay Inc. (NYSE: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the publication of the results of an independent peer-reviewed study titled: "Surgical Technique and Clinically Relevant Resection Cavity Dynamics Following Implantation of Cesium-131 Brachytherapy in Patients With Brain Metastases." 

The paper discusses an institutional review board-approved prospective trial conducted at New York Presbyterian/Weill Cornell Medical Center between 2010 and 2014. During the trial, 30 patients underwent intraoperative Cs-131 brachytherapy following surgical removal of solitary brain metastases. 

New York Presbyterian/Weill Cornell Medical Center sought to minimize toxicity by both shortening the duration of radiation delivery and minimizing cavity shrinkage post-resection. The team used the "seeds-on-a-string" surgical technique in an attempt to stabilize cavity volume and minimize shrinkage. With this technique, seeds are implanted on a string that line the cavity like barrel staves and are held in place with fibrin glue to prevent inward cavity collapse. The study concluded that it was equally important to implant Cs-131 seeds on a string and use fibrin glue to successfully maintain the cavity volume in the first 30 days after the seeds are placed. The technique promoted dose homogeneity and minimized the risk of radiation-induced injury to the surrounding, healthy brain tissue. 

The study was presented at ASTRO's 55th Annual Meeting in Atlanta, GA 2013. The research paper was published online: Wernicke, A. Gabriella, et al. "Surgical Technique and Clinically Relevant Resection Cavity Dynamics Following Implantation of Cesium-131 Brachytherapy in Patients With Brain Metastases."

Neurosurgery. Accessed online December 14, 2015(doi: 10.1227/NEU.0000000000000986). 

Dwight Babcock, Chairman and CEO of IsoRay Medical, stated: "Brain metastases are a grievous problem, with tens of thousands of patients diagnosed each year with metastases from breast, lung, kidney and other primary cancers. Cesium-131 brachytherapy using the "seeds on a string" technique in conjunction with fibrin glue has promise as a radiation treatment for brain metastases since it delivers a very focused dose of radiation to the site of the surgically removed metastasis and spares the rest of the brain from radiation. As a result of these potential benefits, Isoray's Cesium-131 brachytherapy seeds have been deployed in the treatment of brain metastases."

About IsoRay

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement

Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether interest in and use of our products will increase or continue, whether awareness and adoption of our products in the medical community will continue or increase, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information